Scotland's Mironid is moving from discovery into drug development, armed with fresh venture capital from Roche Holding AG and a promising candidate that could shake up the autosomal dominant polycystic kidney disease (ADPKD) space.
Key Takeaways:
- Mironid has raised £35m in total to advance its preclinical ADPKD candidate
Mironid, which raised £4.3m in June 2016 in its Series A financing, has announced an extension of that round, bringing...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
